Obesity Clinical Trial
— STAP-DeltaOfficial title:
A Post-market, Observational Registry With the easyEndoTM Universal Linear Cutting Stapler in Laparoscopic Bariatric Surgery
Verified date | May 2023 |
Source | Duomed |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
The purpose of this observational registry is to evaluate the safety and performance of the easyEndoTM Universal Linear Cutting Stapler and reloads from Ezisurg Medical when used to create anastomoses during laparoscopic bariatric surgery. The goal of the study will be achieved by assessing the device performance and by reporting of peri- and postoperative complications in a prospectively maintained database.
Status | Active, not recruiting |
Enrollment | 200 |
Est. completion date | May 31, 2025 |
Est. primary completion date | April 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient = 18 years of age at registry entry. - Patient and investigator signed and dated the informed consent form prior to the index-procedure. - Patient has a BMI = 35 kg/m2, with one or more related co-morbidities. - Patient has a BMI = 40 kg/m2. - Patient is eligible for laparoscopic bariatric surgery. Exclusion Criteria: - Patient is unable / unwilling to provide informed consent. - Patient has a history of bariatric surgery. - Patient is unable to comply with the registry protocol or proposed follow-up visits. - Patient has a contra-indication for laparoscopic bariatric surgery. |
Country | Name | City | State |
---|---|---|---|
Belgium | AZ Delta vzw | Roeselare |
Lead Sponsor | Collaborator |
---|---|
Duomed |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical) in laparoscopic bariatric surgery. | Conversion rate, number of re-interventions and number of participants with (serious) adverse events = grade II Clavien-Dindo. | At index procedure | |
Primary | To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical) in laparoscopic bariatric surgery. | Number of re-interventions and number of participants with (serious) adverse events = grade II Clavien-Dindo. | At discharge, up to 1 week | |
Primary | To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical) in laparoscopic bariatric surgery. | Number of re-interventions and number of participants with (serious) adverse events = grade II Clavien-Dindo. | Follow-up 1: 3 weeks after the procedure | |
Primary | To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical) in laparoscopic bariatric surgery. | Number of re-interventions and number of participants with (serious) adverse events = grade II Clavien-Dindo. | Follow-up 2: 8 weeks after the procedure | |
Primary | To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical) in laparoscopic bariatric surgery. | Number of re-interventions and number of participants with (serious) adverse events = grade II Clavien-Dindo. | Follow-up 3: 6 months after the procedure | |
Primary | To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical) in laparoscopic bariatric surgery. | Number of re-interventions and number of participants with (serious) adverse events = grade II Clavien-Dindo. | Follow-up 4: 12 months after the procedure | |
Primary | To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical) in laparoscopic bariatric surgery. | Number of re-interventions and number of participants with (serious) adverse events = grade II Clavien-Dindo. | Follow-up 5: 18 months after the procedure | |
Primary | To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical) in laparoscopic bariatric surgery. | Number of re-interventions and number of participants with (serious) adverse events = grade II Clavien-Dindo. | Follow-up 6: 24 months after the procedure | |
Secondary | Device performance | Number of procedures with technical success defined as bariatric surgery as intended, without technical difficulties and without conversion to open laparotomy. | At index procedure | |
Secondary | Device performance | Assessment of device performance (e.g. sharpness of the blade, staple-line formation, etc.). | At index procedure | |
Secondary | Clinical efficacy | Weight loss | Follow-up 1: 3 weeks after the procedure | |
Secondary | Clinical efficacy | Weight loss | Follow-up 2: 8 weeks after the procedure | |
Secondary | Clinical efficacy | Weight loss | Follow-up 3: 6 months after the procedure | |
Secondary | Clinical efficacy | Weight loss | Follow-up 4: 12 months after the procedure | |
Secondary | Clinical efficacy | Weight loss | Follow-up 5: 18 months after the procedure | |
Secondary | Clinical efficacy | Weight loss | Follow-up 6: 24 months after the procedure | |
Secondary | Clinical efficacy | Comorbidity | Follow-up 4: 12 months after the procedure | |
Secondary | Clinical efficacy | Comorbidity | Follow-up 6: 24 months after the procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |